查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1868238

Devic症候群治療市場按治療方法、通路和最終用戶分類 - 全球預測 2025-2032

Devic's Syndrome Treatment Market by Treatment Type, Distribution Channel, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，德維克症候群治療市場將成長至 3.2102 億美元，複合年成長率為 4.82%。

關鍵市場統計數據
基準年 2024 2.2027億美元
預計年份：2025年 2.3071億美元
預測年份 2032 3.2102億美元
複合年成長率 (%) 4.82%

清晰而實用地概述了影響德維克症候群治療決策的臨床實際情況、相關人員的優先事項和操作要務。

本執行摘要全面概述了德維克症候群治療領域的最新臨床和商業性進展，整合了臨床試驗進展、治療模式、監管里程碑以及面向整個醫療價值鏈相關人員的營運考慮。報告首先闡述了該疾病的臨床異質性和不斷發展的治療標準，然後探討了新型標靶治療和現有療法如何重塑患者治療路徑和醫保支付方的互動模式。分析過程中，重點在於提供切實可行的見解，以支援產品開發、報銷策略和臨床專案協調。

科學突破、適應性監管途徑和醫療服務創新將如何共同重塑德維克綜合症的治療選擇和獲取模式？

受科學進步、監管變革和醫療服務模式演變的推動，德維克綜合症的治療格局正在經歷變革性變化，這些因素共同重塑了人們對治療的預期和投資重點。單株抗體研發的突破性進展提供了特異性機制的治療選擇，以取代傳統的廣譜免疫抑制療法，促使臨床醫生重新思考治療順序和長期管理策略。同時，診斷特異性的提高和疾病表現型早期識別使得更有針對性地啟動高效療法成為可能，並正在重塑臨床試驗的患者群體。

評估2025年美國關稅調整對營運和採購的影響及其對治療藥物供應和合約經濟性的下游影響

美國在2025年實施的關稅調整和貿易政策變化，為全球供應鏈和籌資策略引入了新的變數，影響著與德維克症候群相關的治療方法的研發和分銷。依賴跨境採購活性藥物成分、生物製藥或輸注裝置的製造商和經銷商面臨成本結構波動和前置作業時間變化，這會影響其定價策略以及與支付方和醫院的合約談判。儘管治療方法的臨床提案仍然是支付方考慮的首要因素，但不斷上漲的供應鏈成本可能會限制藥物被納入健保目錄，並需要重新評估健康經濟模型以反映不斷上漲的採購成本。

詳細的細分分析，闡述了治療方法、通路和終端用戶環境如何相互作用，從而決定臨床路徑和商業性執行。

細分市場分析揭示了不同治療類型、分銷管道和終端用戶環境之間的顯著差異，這些差異共同塑造了臨床路徑和商業性策略。按治療類型分類，糖皮質激素仍然是急性期治療的基礎選擇，分為靜脈注射和口服兩種劑型，這決定了給藥方式和監測要求。Azathioprine和Mycophenolate Mofetil等免疫抑制劑繼續作為維持治療藥物發揮作用，其安全性監測和依從性要求各不相同。單株抗體，特別是Eculizumab和伊奈利珠單抗，透過標靶機制重新定義了長期疾病管理，這需要低溫運輸物流和專門的報銷通訊協定。血漿置換療法採用自動化和手動兩種方式進行，對人員配備、設備和療程安排都有影響。包括疼痛管理和物理治療在內的支持性護理對於整體性的患者照護和最佳化生活品質至關重要。

區域監管差異、醫療保健融資模式和臨床能力差異如何影響德維茲症候群治療的可近性和接受度

區域趨勢在治療方法研發和准入的策略規劃中發揮核心作用，因為它們深刻影響臨床實踐模式、監管方式和支付方環境。在美洲，先進的法規結構和集中的臨床專家中心促進了高效治療方法的早期應用，而報銷談判和預算限制則決定了療法能否廣泛普及。該地區的醫療管理系統和綜合醫療網路通常需要強力的療效比較證據和真實世界結果，以支持藥物目錄的納入和使用管理政策。

深入了解以臨床差異化、卓越營運和綜合患者支援服務為核心的競爭策略，這些策略定義了德維克綜合症治療領域的市場領導地位。

德維克症候群治療領域的競爭格局呈現出多元化的特點，既有成熟的非專利免疫抑制劑，也有擁有特化生物製藥的新興企業，以及提供輸液和血漿置換服務供應商。各企業的關鍵策略正趨向於差異化的臨床證據、持久的安全性以及能夠降低治療障礙的綜合患者支持服務。生物製藥申辦方致力於證明其長期療效和降低復發率，同時投資擴大生產規模、提高分銷可靠性，並與支付方協商基本契約。這些申辦者也優先收集真實世界證據，以證明其比較優勢並支持擴大適應症。

為產業領導者提供切實可行的策略行動，將證據產生、供應鏈韌性和個人化配送連結起來，以確保療法的持續推廣應用。

行業領導者應優先採取一系列果斷行動，將科學進步轉化為永續的臨床和商業性成功。首先，應協調臨床開發和核准後證據產生計劃，以滿足支付方和臨床醫生對長期療效和相對有效性的期望，從而降低報銷談判中的不確定性，並支持適應症差異化。其次，應透過供應商多元化、關鍵製造地地域多角化以及實施關稅應對計劃來增強供應鏈韌性，以減輕採購中斷的影響，確保治療的連續性。

我們採用穩健的多來源調查方法，結契約儕審查的證據、相關利益者訪談、供應鏈分析和專家檢驗，以確保可靠性和實用性。

本分析的調查方法整合了多方面的資料檢驗和嚴格的檢驗程序，以確保其可靠性和對決策者的相關性。此方法首先對同行評審的臨床文獻、監管核准和已發表的臨床試驗結果進行全面審查，以闡明治療機制、療效終點和安全性訊號。此外，還對治療指南和支付方決策框架進行了檢驗，以了解報銷標準和臨床應用促進因素。

簡潔扼要的總結強調了需要採取綜合證據策略、提高營運韌性以及製定在地化的准入計劃，才能充分發揮治療的潛力。

總之，隨著生物目標、不斷演變的監管機制和適應性護理模式的融合，德維克氏症候群的治療和商業格局正處於一個關鍵的轉折點，這些因素共同重新定義了治療標準。相關人員必須權衡高效、針對特異性機制的治療方法的潛力與分銷、報銷和長期監測等方面的實際考慮。供應鏈和政策趨勢凸顯了業務營運中韌性和前瞻性的重要性，而市場區隔和區域動態則強調了製定客製化市場進入策略的必要性。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 針對視神經脊髓炎的治療方法，隨著特異性和安全性的提高，其應用迅速普及。
  • 將真實世界數據和病患登記資訊整合到德維克症候群的臨床決策支援系統中
  • 針對 Devic 症候群的水通道蛋白 4標靶治療的單株抗體研發管線獲得了越來越多的投資。
  • 生物相似藥和新型生物製藥的出現，正在推動 Devic 症候群治療領域的成本競爭。
  • 遠端醫療和遠端監測設備在脊髓炎患者照護中日益重要。
  • 擴大基因和生物標記研究，以實現針對德維克症候群的個人化治療策略。
  • 製藥公司和生物技術公司之間的合作夥伴關係加速了德維克症候群治療領域的創新。

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 德維克症候群治療市場（依治療方法分類）

  • 皮質類固醇
    • 靜脈注射
    • 口服
  • 免疫抑制劑
    • Azathioprine
    • Mycophenolate Mofetil
  • 單株抗體
    • Eculizumab
    • 伊尼利珠單抗
  • 血漿置換
    • 自動的
    • 手動的
  • 支持性護理
    • 疼痛管理
    • 物理治療

9. 德維克綜合症治療市場（按分銷管道分類）

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第10章 依最終用戶分類的德維克症候群治療市場

  • 家庭醫療保健
  • 醫院
  • 專科診所

第11章 Devic 症候群治療市場：按地區分類

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第12章 德維克症候群治療市場（按組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

13. 各國德維克氏症候群治療市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Alexion Pharmaceuticals, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Viela Bio, Inc.
    • Chugai Pharmaceutical Co., Ltd.
    • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-CB04E05660A7

The Devic's Syndrome Treatment Market is projected to grow by USD 321.02 million at a CAGR of 4.82% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 220.27 million
Estimated Year [2025] USD 230.71 million
Forecast Year [2032] USD 321.02 million
CAGR (%) 4.82%

A clear and actionable overview that frames clinical realities, stakeholder priorities, and operational imperatives shaping Devic's syndrome therapeutic decision-making

This executive summary introduces a consolidated briefing on current clinical and commercial developments in Devic's syndrome therapeutics, synthesizing clinical trial progress, treatment paradigms, regulatory milestones, and operational considerations for stakeholders across the healthcare value chain. The narrative begins by framing the clinical heterogeneity of the disorder and the evolving standards of care, then moves into how novel targeted therapies and established approaches are reshaping patient pathways and payer dialogues. Throughout the analysis, emphasis is placed on actionable intelligence that supports product development, reimbursement strategy, and clinical program alignment.

Given the multiplicity of therapeutic classes under evaluation, the introduction foregrounds the mechanisms of action, delivery modalities, and care settings that define decision points for clinicians, hospital systems, and specialty clinics. The briefing contextualizes recent approvals and label expansions alongside utilization patterns seen in hospital pharmacies, retail and online distribution channels, and home healthcare programs. It also outlines key stakeholder motivations, including clinicians' priorities for durable efficacy and safety, payers' concerns about cost-effectiveness, and patients' needs for reduced treatment burden.

As an opening synthesis, the introduction clarifies scope, highlights the imperative for integrated cross-functional planning, and sets the stage for subsequent sections that examine landscape shifts, policy impacts, segmentation insights, regional dynamics, competitive positioning, recommendations, and the research methods applied. This structured approach ensures readers can translate evidence into strategy while maintaining clarity on clinical realities and operational constraints.

How scientific breakthroughs, adaptive regulatory pathways, and care delivery innovations are collectively reshaping therapy selection and access dynamics for Devic's syndrome

The therapeutic landscape for Devic's syndrome is undergoing transformative shifts driven by scientific advances, regulatory changes, and evolving care delivery models that together redefine treatment expectations and investment priorities. Breakthroughs in monoclonal antibody development have introduced mechanism-specific options that challenge prior reliance on broad immunosuppression, prompting clinicians to rethink treatment sequencing and long-term management strategies. In parallel, improvements in diagnostic specificity and earlier identification of disease phenotypes are enabling more targeted initiation of high-efficacy therapies while reshaping enrollment pools for clinical studies.

Concurrently, regulatory pathways have adapted to accommodate accelerated reviews for therapies demonstrating substantial benefit on validated clinical endpoints, which has accelerated time-to-market for select biologics. This regulatory momentum has induced greater competition among sponsors to secure label differentiation through head-to-head studies, real-world evidence generation, and biomarker-driven subpopulation data. At the delivery level, the expansion of home-based care and scaled access to infusion services outside traditional hospital settings have altered distribution and reimbursement conversations, compelling payers and providers to negotiate new care models that balance cost, convenience, and clinical oversight.

Taken together, these shifts create both strategic risk and opportunity: organizations that invest in differentiated evidence strategies, robust post-approval surveillance, and adaptive distribution partnerships will be better positioned to secure clinician adoption and payer acceptance, while those slow to align with the new clinical paradigms may face intensified access barriers and constrained uptake.

Assessing the operational and procurement consequences of United States tariff adjustments in 2025 and their downstream effects on therapeutic availability and contractual economics

Recent tariff developments and trade policy adjustments implemented by the United States in 2025 have introduced new variables into global supply chains and procurement strategies that affect the development and distribution of therapies relevant to Devic's syndrome. Manufacturers and distributors that rely on cross-border sourcing for active pharmaceutical ingredients, biologic components, or infusion devices have encountered shifting cost structures and lead-time variability, which in turn influence pricing strategies and contracting conversations with payers and hospitals. While the clinical value proposition of a therapy remains primary in payer deliberations, increased supply-chain costs can constrain formulary placements and require revised health-economic models to reflect higher procurement expenses.

In response, several manufacturers have prioritized supply-chain resilience by diversifying sourcing, regionalizing production hubs, and negotiating tariff-mitigation clauses into supplier contracts. These operational adjustments are particularly pronounced for platform-dependent products such as monoclonal antibodies and plasm a-exchange consumables, where tight tolerances and specialized manufacturing inputs make near-term substitution challenging. Moreover, distribution partners and hospital pharmacies are reassessing inventory strategies to buffer against transit disruptions, which has implications for working capital and on-hand availability for patients requiring urgent treatment initiation.

Ultimately, the cumulative impact of tariff policy in 2025 has emphasized the need for integrated commercial planning that incorporates trade policy scenarios into procurement, contracting, and pricing models. Stakeholders who proactively model tariff-driven contingencies and engage in collaborative sourcing partnerships will be better equipped to preserve uninterrupted access to critical therapies for patients living with Devic's syndrome.

Detailed segmentation insights explaining how treatment modalities, distribution channels, and end-user settings interact to determine clinical pathways and commercial execution

Segmentation analysis reveals divergent dynamics across treatment types, distribution channels, and end-user settings that together shape clinical pathways and commercial approaches. By treatment type, corticosteroids remain a foundational acute management option and are sub-classified into intravenous and oral formulations that inform administration setting and monitoring requirements; immunosuppressants such as azathioprine and mycophenolate mofetil continue to serve maintenance roles with distinct safety monitoring and adherence profiles; monoclonal antibodies, notably eculizumab and inebilizumab, are redefining long-term disease control considerations through targeted mechanisms that demand cold-chain logistics and specialized reimbursement protocols; plasma exchange appears in both automated and manual modalities with implications for staffing, capital equipment, and session scheduling; and supportive therapy, which encompasses pain management and physiotherapy, remains indispensable for holistic patient care and quality-of-life optimization.

When examining distribution channels, hospital pharmacies, online pharmacies, and retail pharmacies present unique advantages and limitations that affect access, adherence, and continuity of care. Hospital pharmacies facilitate complex administration and immediate clinical oversight, online pharmacies offer convenience and potentially expanded geographic reach with unique regulatory compliance needs, and retail pharmacies serve as critical touchpoints for patient counseling and repeat dispensing. From an end-user perspective, home healthcare, hospitals, and specialty clinics each operate with distinct operational constraints and reimbursement frameworks. Home healthcare supports decentralization and patient convenience but requires rigorous care coordination and safety protocols; hospitals enable acute management and multidisciplinary collaboration; and specialty clinics concentrate expertise and may accelerate adoption of novel therapies through focused clinician experience and structured follow-up.

These segmentation layers interact to influence clinical decision-making and commercial execution. For instance, a monoclonal antibody requiring infusion and specialized monitoring is typically routed through hospital or specialty clinics and dispensed via hospital pharmacy channels, whereas oral corticosteroids and common immunosuppressants may traverse retail and online pharmacies, enabling distributed access. Understanding these interdependencies is essential for aligning manufacturing, distribution, and patient-support programs with real-world care pathways.

How regional regulatory diversity, healthcare financing models, and clinical capacity variations shape differential access and adoption of therapies for Devic's syndrome

Regional dynamics exert substantial influence on clinical practice patterns, regulatory approaches, and payer environments, and they therefore play a central role in strategic planning for therapy development and access. In the Americas, advanced regulatory frameworks and concentrated centers of clinical expertise drive early adoption of high-efficacy interventions, while reimbursement negotiations and budgetary constraints shape pathways to broad access. Managed care systems and integrated delivery networks in this region frequently demand robust comparative effectiveness evidence and real-world outcomes to support formulary inclusion and utilization management policies.

Europe, Middle East & Africa presents a heterogeneous landscape where national regulatory agencies, diverse healthcare financing models, and varying degrees of clinical capacity lead to differentiated adoption curves. In some European markets, centralized pricing and health-technology assessment processes require comprehensive evidence dossiers and health-economic modeling; conversely, markets within the Middle East and Africa may experience constrained specialty care infrastructure, necessitating tailored distribution approaches and capacity-building initiatives to improve diagnosis and treatment delivery.

In the Asia-Pacific region, rapid regulatory modernization in several markets is accelerating the entry of innovative therapies, while distinct payer priorities and out-of-pocket payment models in other jurisdictions influence patient access and affordability. Supply-chain proximity within Asia-Pacific can be advantageous for manufacturers seeking regional manufacturing hubs, but local regulatory requirements, importation rules, and country-specific clinical expectations require adaptive regulatory and market-access strategies. Across all regions, coordinated stakeholder engagement, evidence generation aligned with local decision-makers, and flexible delivery models will be critical to bridging clinical innovation and patient access.

Insight into competitive strategies where clinical differentiation, operational excellence, and integrated patient-support services determine market leadership in Devic's syndrome care

Competitive positioning within the Devic's syndrome therapeutic landscape is characterized by a mix of established generic immunosuppressants, specialized biologic entrants, and service providers offering infusion and plasma exchange capabilities. Key corporate strategies are clustering around differentiated clinical evidence, durable safety profiles, and integrated patient-support services that reduce treatment friction. Biologic sponsors focus on demonstrating long-term efficacy and reduced relapse rates while investing in manufacturing scale-up, distribution reliability, and value-based contracting conversations with payers. These sponsors also prioritize real-world evidence collection to substantiate comparative benefit and inform label expansions.

Manufacturers of traditional immunosuppressants and corticosteroids emphasize longstanding clinical familiarity, cost-effectiveness in certain care scenarios, and well-understood safety-monitoring pathways. Their commercial approach tends to concentrate on optimizing supply continuity, ensuring broad distribution through hospital and retail channels, and supporting clinicians with pragmatic guidance for maintenance therapy. Providers of plasma exchange technologies and services are differentiating through automation, capacity-building partnerships with hospitals and specialty clinics, and alignment with hybrid care models that shift certain services closer to the patient.

Across the competitive set, successful firms are those that integrate clinical differentiation with operational excellence in cold-chain logistics, payer engagement, and clinician education. Strategic collaborations between biologic developers and service providers that streamline administration and monitoring pathways are emerging as a critical axis for delivering comprehensive value to healthcare systems and patients alike.

A pragmatic set of strategic actions for industry leaders to link evidence generation, supply-chain resilience, and tailored distribution to secure durable therapy adoption

Industry leaders should prioritize a sequence of decisive actions to convert scientific advances into sustainable clinical and commercial success. First, align clinical development and post-approval evidence-generation plans to address payer and clinician expectations for long-term outcomes and comparative effectiveness, thereby reducing uncertainty during reimbursement negotiations and supporting label differentiation. Second, invest in supply-chain resilience by diversifying suppliers, regionalizing critical manufacturing nodes, and implementing tariff-contingency planning to mitigate procurement disruptions and preserve treatment continuity.

Third, design distribution and patient-support programs that reflect segmentation realities: tailor pharmacy pathways for oral and infusion therapies, develop robust home healthcare protocols where appropriate, and partner with specialty clinics to accelerate clinician familiarity and patient monitoring. Fourth, engage proactively with regional health authorities and payers to co-create value frameworks that recognize both clinical benefit and system-level efficiencies, employing real-world data to substantiate health-economic narratives. Fifth, foster collaborative partnerships among biologic developers, device and service providers, and clinical centers to streamline administration workflows and reduce patient burden.

By executing these priorities in a coordinated manner-linking clinical evidence, operational readiness, and payer engagement-industry leaders can increase the probability of durable adoption while demonstrating responsible stewardship of healthcare resources.

A robust multi-source methodology combining peer-reviewed evidence, stakeholder interviews, supply-chain analysis, and expert validation to ensure credible and actionable insights

The research methodology underpinning this analysis integrates multi-source data triangulation with rigorous validation steps designed to ensure credibility and relevance for decision-makers. The approach began with a comprehensive review of peer-reviewed clinical literature, regulatory approvals, and published clinical-trial results to map therapeutic mechanisms, efficacy endpoints, and safety signals. This literature review was complemented by an examination of treatment guidelines and payer decision frameworks to understand reimbursement criteria and clinical adoption drivers.

Primary data collection included structured interviews with clinicians, hospital pharmacists, specialty clinic managers, and distribution executives to capture frontline perspectives on treatment selection, administration logistics, and patient-support needs. Supply-chain analyses leveraged publicly available manufacturing and trade data to assess potential vulnerabilities and the operational impact of policy shifts. Where applicable, real-world evidence sources and registry data were consulted to contextualize treatment patterns and durability of response outside controlled trial environments.

All findings underwent cross-validation through expert panel review and sensitivity checks to reconcile divergent stakeholder viewpoints. Analytical techniques combined qualitative thematic analysis with scenario planning to surface strategic implications and actionable recommendations. Ethical research practices, transparency in source attribution, and adherence to data privacy standards were maintained throughout the process to ensure robustness and reproducibility of insights.

A concise synthesis emphasizing the need for integrated evidence strategies, operational resilience, and regionally adaptive access plans to realize therapeutic potential

In conclusion, the therapeutic and commercial environment for Devic's syndrome is in a period of meaningful transition as targeted biologics, evolving regulatory mechanisms, and adaptive care models converge to redefine standards of care. Stakeholders must reconcile the promise of high-efficacy, mechanism-specific therapies with practical considerations around distribution, reimbursement, and long-term monitoring. Supply-chain and policy developments have amplified the importance of resilience and operational foresight, while segmentation and regional dynamics underscore the need for customized market-access approaches.

Successful navigation of this landscape requires integrated strategies that marry rigorous evidence generation with pragmatic delivery solutions, regional regulatory acumen, and sustained payer engagement. Organizations that invest in comprehensive post-approval data collection, flexible distribution networks, and collaborative partnerships across the care continuum will be positioned to translate scientific innovation into meaningful patient outcomes and system-level value. Ultimately, the intersection of clinical differentiation and operational excellence will determine which therapies gain broad clinician acceptance and secure reliable patient access.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rapid adoption of neuromyelitis optica therapies with improved specificity and safety profiles
  • 5.2. Integration of real-world evidence and patient registries in clinical decision support for Devic's syndrome
  • 5.3. Increasing investment in monoclonal antibody pipeline focusing on aquaporin-4 targeted treatments for Devic's syndrome
  • 5.4. Emergence of biosimilars and novel biologics driving cost competition in Devic's syndrome management
  • 5.5. Growing significance of telemedicine and remote monitoring devices for neuromyelitis optica patient care
  • 5.6. Expansion of genetic and biomarker research enabling personalized treatment strategies for Devic's syndrome
  • 5.7. Collaborative partnerships between pharma and biotech accelerating Devic's syndrome therapy innovation

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Devic's Syndrome Treatment Market, by Treatment Type

  • 8.1. Corticosteroids
    • 8.1.1. Intravenous
    • 8.1.2. Oral
  • 8.2. Immunosuppressants
    • 8.2.1. Azathioprine
    • 8.2.2. Mycophenolate Mofetil
  • 8.3. Monoclonal Antibodies
    • 8.3.1. Eculizumab
    • 8.3.2. Inebilizumab
  • 8.4. Plasma Exchange
    • 8.4.1. Automated
    • 8.4.2. Manual
  • 8.5. Supportive Therapy
    • 8.5.1. Pain Management
    • 8.5.2. Physiotherapy

9. Devic's Syndrome Treatment Market, by Distribution Channel

  • 9.1. Hospital Pharmacies
  • 9.2. Online Pharmacies
  • 9.3. Retail Pharmacies

10. Devic's Syndrome Treatment Market, by End User

  • 10.1. Home Healthcare
  • 10.2. Hospitals
  • 10.3. Specialty Clinics

11. Devic's Syndrome Treatment Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Devic's Syndrome Treatment Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Devic's Syndrome Treatment Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Analysis
    • 14.3.1. Alexion Pharmaceuticals, Inc.
    • 14.3.2. F. Hoffmann-La Roche Ltd.
    • 14.3.3. Viela Bio, Inc.
    • 14.3.4. Chugai Pharmaceutical Co., Ltd.
    • 14.3.5. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 9. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. NORTH AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. LATIN AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. EUROPE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. MIDDLE EAST DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASEAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GCC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPEAN UNION DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. BRICS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. G7 DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. NATO DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. DEVIC'S SYNDROME TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 26. DEVIC'S SYNDROME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. DEVIC'S SYNDROME TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY AZATHIOPRINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY AZATHIOPRINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY AZATHIOPRINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY AZATHIOPRINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY AZATHIOPRINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY AZATHIOPRINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY ECULIZUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY ECULIZUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY ECULIZUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY ECULIZUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY ECULIZUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY ECULIZUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY INEBILIZUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY INEBILIZUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY INEBILIZUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY INEBILIZUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY INEBILIZUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY INEBILIZUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY AUTOMATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY AUTOMATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY AUTOMATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY AUTOMATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY AUTOMATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY AUTOMATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MANUAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MANUAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MANUAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MANUAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MANUAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MANUAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PHYSIOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PHYSIOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PHYSIOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PHYSIOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PHYSIOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PHYSIOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2025-2032 (USD MILLION)
  • TABLE 155. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2025-2032 (USD MILLION)
  • TABLE 161. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 163. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 165. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 166. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. NORTH AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 170. NORTH AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
  • TABLE 172. NORTH AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2025-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 174. NORTH AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 176. NORTH AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2025-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 180. NORTH AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 182. NORTH AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 184. NORTH AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. LATIN AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 188. LATIN AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
  • TABLE 190. LATIN AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2025-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 192. LATIN AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 194. LATIN AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2024 (USD MILLION)
  • TABLE 196. LATIN AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2025-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 198. LATIN AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 200. LATIN AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 202. LATIN AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. MIDDLE EAST DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. MIDDLE EAST DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
  • TABLE 244. MIDDLE EAST DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2025-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 246. MIDDLE EAST DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 248. MIDDLE EAST DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2024 (USD MILLION)
  • TABLE 250. MIDDLE EAST DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2025-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 252. MIDDLE EAST DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 254. MIDDLE EAST DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 256. MIDDLE EAST DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 257. AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
  • TABLE 262. AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2025-2032 (USD MILLION)
  • TABLE 263. AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 264. AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 265. AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 266. AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 267. AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2024 (USD MILLION)
  • TABLE 268. AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2025-2032 (USD MILLION)
  • TABLE 269. AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 270. AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 271. AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 272. AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 273. AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 274. AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 275. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
  • TABLE 280. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2025-2032 (USD MILLION)
  • TABLE 281. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 282. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 283. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 284. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 285. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2024 (USD MILLION)
  • TABLE 286. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2025-2032 (USD MILLION)
  • TABLE 287. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 288. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 289. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 290. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 291. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 292. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 295. ASEAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 296. ASEAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 297. ASEAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. ASEAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 299. ASEAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
  • TABLE 300. ASEAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2025-2032 (USD MILLION)
  • TABLE 301. ASEAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 302. ASEAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 303. ASEAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY M